Reaktionsgleichung
[CH2:1]([N:3]1[CH2:8][CH2:7][NH:6][CH2:5][CH2:4]1)[CH3:2].[CH2:9]([O:11][C:12]1[CH:17]=[CH:16][C:15]([S:18](Cl)(=[O:20])=[O:19])=[CH:14][C:13]=1[C:22]1[NH:27][C:26](=[O:28])[N:25]2[C:29]([CH3:35])=[N:30][C:31]([CH2:32][CH2:33][CH3:34])=[C:24]2[N:23]=1)[CH3:10]>ClCCl>[CH2:9]([O:11][C:12]1[CH:17]=[CH:16][C:15]([S:18]([N:6]2[CH2:7][CH2:8][N:3]([CH2:1][CH3:2])[CH2:4][CH2:5]2)(=[O:20])=[O:19])=[CH:14][C:13]=1[C:22]1[NH:27][C:26](=[O:28])[N:25]2[C:29]([CH3:35])=[N:30][C:31]([CH2:32][CH2:33][CH3:34])=[C:24]2[N:23]=1)[CH3:10]Komponenten
4
Edukt 2
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 1
Versuchsvorschrift
83 mg (0.73 mmol) of N-ethylpiperazine are added to a solution of 100 mg (0.24 mmol) of 4-ethoxy-3-(6-methyl-4-oxo-8-propyl-3,4-dihydro-imidazo[1,5-a]-[1,3,5]triazin-2-yl)-benzenesulfonyl chloride (example VI) in 5 ml of dichloromethane and the reaction mixture is stirred at room temperature for 2 hours. After chromatographic purification (dichloromethane/methanol=95:5), 104 mg (87%) of 2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulfonyl)-phenyl]-6-methyl-8-propyl-3H-imidazo[1,5-a][1,3,5]triazin-4-one are obtained.
Aufarbeitung
- customAfter chromatographic purification (dichloromethane/methanol=95:5), 104 mg (87%) of 2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulfonyl)-phenyl]-6-methyl-8-propyl-3H-imidazo[1,5-a][1,3,5]triazin-4-one
- customare obtained
Quellen und Nachweise
- ORD-Eintrag
- ord-1e7af79867e74406a2bab6bfb9b7df2d
- Quelldatensatz
- uspto-grants-2006_08
- Patentnummer
- US07091203B2
Verknüpfte Notizen
Wird geladen…